NEW YORK, Nov. 12, 2024 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global Glaucoma Therapeutics Market is experiencing significant growth owing to the ...

NORTHBROOK, Ill., Nov. 12, 2024 /PRNewswire/ -- Endevica Bio's experimental peptide to prevent weight loss associated with ...

Currently, there is no FDA-approved treatment for cancer anorexia cachexia syndrome. ART26.12, Artelo's lead Fatty Acid ...

Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients.

Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials.

The Arkansas Integrative Metabolic Research Center will host its annual symposium on Thursday in the Arkansas Union Ballroom with presentations starting at 8:15 a.m. and poster sessions at 10:30 a.m.

A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...